The estimated Net Worth of Jeffrey Trigilio is at least $1.57 Million dollars as of 21 December 2023. Mr Trigilio owns over 1,920 units of Cullinan Oncology stock worth over $1,508,864 and over the last 4 years he sold CGEM stock worth over $62,550.
Mr has made over 13 trades of the Cullinan Oncology stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 1,920 units of CGEM stock worth $16,320 on 21 December 2023.
The largest trade he's ever made was exercising 15,000 units of Cullinan Oncology stock on 8 September 2021 worth over $64,500. On average, Mr trades about 1,604 units every 54 days since 2021. As of 21 December 2023 he still owns at least 83,919 units of Cullinan Oncology stock.
You can see the complete history of Mr Trigilio stock trades at the bottom of the page.
Jeffrey Trigilio is the CFO & Treasurer at Cullinan Oncology.
Mr Trigilio is 37, he's been the CFO & Treasurer of Cullinan Oncology since . There are 7 older and no younger executives at Cullinan Oncology. The oldest executive at Cullinan Oncology, LLC is Dr. Patrick A. Baeuerle Ph.D., 63, who is the Co-Founder & Acting Chief Scientific Officer of Biologics.
Jeffrey's mailing address filed with the SEC is C/O CULLINAN ONCOLOGY, INC., ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142.
Over the last 4 years, insiders at Cullinan Oncology have traded over $29,405,190 worth of Cullinan Oncology stock and bought 2,950,136 units worth $38,299,215 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Ansbert Gadicke, and Morana Jovan Embiricos. On average, Cullinan Oncology executives and independent directors trade stock every 14 days with the average trade being worth of $914,589. The most recent stock trade was executed by Jennifer Michaelson on 5 September 2024, trading 8,000 units of CGEM stock currently worth $144,720.
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Cullinan Oncology executives and other stock owners filed with the SEC include: